ELITE PHARMACEUTIC COM USD0.01 (ELTP)

0.19
0.02 14.57
OTC
Prev Close 0.17
Open 0.17
Day Low/High 0.17 / 0.20
52 Wk Low/High 0.11 / 0.44
Volume 4.58M
Exchange OTC
Shares Outstanding 733.72B
Market Cap 122.53M
Div & Yield N.A. (N.A)

Latest News

Elite Pharmaceuticals, Inc. Reports Financial Results For The First Quarter Of Fiscal Year 2017 And Provides Conference Call Information

Elite Pharmaceuticals, Inc. Reports Financial Results For The First Quarter Of Fiscal Year 2017 And Provides Conference Call Information

Conference Call Scheduled for Thursday, August 11th  at 11:00 AM EDT

Elite Pharmaceuticals Announces Changes To Their Board Of Directors

Elite Pharmaceuticals Announces Changes To Their Board Of Directors

Gene Pfeifer Joins Elite's Board

Elite Announces U.S. FDA Priority Review Designation For SequestOx™ NDA

Elite Announces U.S. FDA Priority Review Designation For SequestOx™ NDA

SequestOx™ NDA Submission Accepted for Review

Elite Pharmaceuticals, Inc. Reports Strong Growth For Third Quarter Of Fiscal Year 2016

Elite Pharmaceuticals, Inc. Reports Strong Growth For Third Quarter Of Fiscal Year 2016

Conference Call Scheduled for Wednesday, February 10th at 11:30 AM EST

Elite Pharmaceuticals, Inc. To Host Conference Call To Discuss 3rd Quarter 2016 Financial Results On February 10, 2016

Elite Pharmaceuticals, Inc. To Host Conference Call To Discuss 3rd Quarter 2016 Financial Results On February 10, 2016

Financials for 3rd Quarter Ended December 31, 2015 Will be Released on February 9, 2016

FDA Approves Waiver Of NDA Filing Fee For Elite Pharmaceuticals

FDA Approves Waiver Of NDA Filing Fee For Elite Pharmaceuticals

Elite to Submit New Drug Application for ELI-200

Elite Pharmaceuticals, Inc. Reports Strong Growth For Second Quarter Of Fiscal Year 2016

Elite Pharmaceuticals, Inc. Reports Strong Growth For Second Quarter Of Fiscal Year 2016

Webcast and Conference Call Scheduled for Tuesday, November 10th at 11:00 AM EST

Elite Pharmaceuticals, Inc. To Host Conference Call And Webcast To Discuss 2nd Quarter 2016 Financial Results On November 10, 2015

Elite Pharmaceuticals, Inc. To Host Conference Call And Webcast To Discuss 2nd Quarter 2016 Financial Results On November 10, 2015

Financials for 2nd Quarter Ended September 30, 2015 will be released on November 9, 2015

Elite Pharmaceuticals, Inc. Reports Record Revenues For First Quarter Of Fiscal Year 2016

Elite Pharmaceuticals, Inc. Reports Record Revenues For First Quarter Of Fiscal Year 2016

Webcast and Conference Call Scheduled for Tuesday, August 11th at 11:00 AM EDT

Elite Pharmaceuticals, Inc. To Host Conference Call And Webcast To Discuss 1st Quarter 2016 Financial Results On August 11, 2015

Elite Pharmaceuticals, Inc. To Host Conference Call And Webcast To Discuss 1st Quarter 2016 Financial Results On August 11, 2015

Financials for 1st Quarter Ended June 31, 2015 Will be Released on August 10, 2015

CORRECTION -- Elite Pharmaceuticals, Inc. To Host Conference Call And Webcast To Discuss Year End 2015 Financial Results On June 16, 2015

CORRECTION -- Elite Pharmaceuticals, Inc. To Host Conference Call And Webcast To Discuss Year End 2015 Financial Results On June 16, 2015

Financials for Year Ended March 31, 2015 Will be Released on June 15, 2015

Elite Pharmaceuticals, Inc. To Host Conference Call And Webcast To Discuss Year End 2015 Financial Results On June 16, 2015

Elite Pharmaceuticals, Inc. To Host Conference Call And Webcast To Discuss Year End 2015 Financial Results On June 16, 2015

Financials for Year Ended March 31, 2015 Will be Released on June 15, 2015

Elite Pharmaceuticals And Epic Pharma Enter Into A Sales And Distribution Licensing Agreement For Abuse-Deterrent ELI-200

Elite Pharmaceuticals And Epic Pharma Enter Into A Sales And Distribution Licensing Agreement For Abuse-Deterrent ELI-200

Elite Pharmaceuticals Announces Initiation of Phase 3 Study for ELI-200

Elite Pharmaceuticals Announces Launch Of Generic Hydroxyzine Tablets

Elite Pharmaceuticals Announces Launch Of Generic Hydroxyzine Tablets

Elite Pharmaceuticals Completes Dosing for Two ELI-200 Studies